
|Videos|August 10, 2021
Dr. Ketan K. Badani on how genomic tests help facilitate patient discussions
Author(s)Urology Times staff
“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.
Advertisement
In this video, Ketan K. Badani, MD, discusses how genomic tests such as Oncotype DX help him discuss treatment options for patients with low-risk or early-stage prostate cancer. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Kevin Zorn, MD, on selecting among different MIST options for BPH
5











